The Phase 2 ASPEN-06 interim analysis showed an ORR of 52% for the evorpacept combination treatment compared to 22% for the control group. What factors contributed to this significant difference in response rates between the two groups?

With the mDOR not yet reached for the evorpacept combination treatment arm and being 7.4 months for the control group, what implications does this have for the long-term efficacy of evorpacept in treating HER2-positive gastric/GEJ cancer?

The safety profile of evorpacept was consistent with previous clinical trials and was well-tolerated. Were there any specific adverse events or side effects observed that could impact its future use?

The interim results showed favorable efficacy compared to the RAINBOW study's results for CYRAMZA + paclitaxel. How does evorpacept's performance set it apart from other treatments in the same category?

Dr. Sophia Randolph mentioned evorpacept's potential as a "first-in-class foundational immunotherapy." Can you elaborate on what this means and how it differentiates evorpacept from other therapies in the market?

The ASPEN-06 trial allowed for patients who had prior treatments with KEYTRUDA (pembrolizumab) and ENHERTU. How did the inclusion of patients with these prior treatments impact the trial's results, and what does it suggest about evorpacept's efficacy in a diverse patient population?

With the final analysis of the Phase 2 ASPEN-06 study expected in Q2 2024 and the initiation of the Phase 3 portion in late 2024, what are the key milestones and expectations for evorpacept's development pipeline in the coming years, and what is your view of that?